October 10, 2024 — Coherent Biopharma (“Coherent”) announced that the U.S. Food and Drug Administration (FDA) has grant...
On June 24, 2024, local time, the U.S. Food and Drug Administration (FDA) notified the approval of Orphan Drug Designation (ODD) f...
ASCO 2024 Highlights: Research findings of CBP-1008 and CBP-1018 once again attract global attention
The American Society of Clinical Oncology (ASCO) Annual Meeting 2024 held from May 31 to June 4 in Chicago, USA. At this year...
Recently, Coherent Biopharma disclosed the latest preclinical research progress of CBP-8008, at the 2024 American Association...
From March 12 to 15, 2024, the 14th World Antibody-Drug Conjugate Conference (World ADC) was held in London, UK. Dr. Guitao Wang,...
On October 18, 2023, Dr. Robert Huang, Founder, Chairman, and CEO of Coherent Biopharma, unveiled the latest clinical data on the company's leading pipeline product, CBP-1008, at the 14th World ADC Conference.
Coherent Biopharma announced today that their proprietary second-generation dual-ligand conjugate drug, CBP-1019, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) on …
Coherent Biopharma announced that clinical data will be presented in the form of a poster at the 2023 European Society for Medical...